Navigation Links
REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
Date:1/17/2012

MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a peer-reviewed journal with broad, multidisciplinary readership. REVIVE (TA-301) was a randomized, placebo-controlled, phase 3 study evaluating the safety and efficacy of avanafil, an investigational drug currently under review by the Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED).  In addition to significant improvements in erectile function and low rates of side effects common to phosphodiesterase type 5  inhibitors, the study also found that patients who attempted intercourse within 15 minutes of dosing were successful 64%, 67% and 71% of the time with 50, 100 and 200mg of avanafil treatment, respectively, versus 27% for placebo (p < 0.0001). The data suggest that avanafil may provide a rapid-onset, well-tolerated and effective treatment option for erectile dysfunction.

"While PDE-5 inhibitors are currently used as first-line therapy for treatment of ED in the general population, what's new and novel about avanafil is that it has a fast onset of action and high selectivity," said lead Investigator Irwin Goldstein, MD, Director of San Diego Sexual Medicine at Alvarado Hospital. "For patients, this means that avanafil, if approved, could be taken on-demand with potentially fewer side effects." 

An overview of the results as published in JSM is as follows:

  • Following 12 weeks of treatment, without restrictions on food or alcohol, all three doses of avanafil (50mg, 100mg and 200mg) were significantly superior to placebo for all primary endpoints (p </= 0.001). 
  • A secondary analysis using Sexual Encounter Profile, question 3 (SEP 3) to ev
    '/>"/>

SOURCE VIVUS
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
2. Secret of sandcastle construction could help revive ancient building technique, researchers say
3. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
4. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
5. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
8. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
11. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... & Boston, MA (PRWEB) July 28, 2014 ... agreements with two researchers to further develop potential treatments ... malignant brain tumor, in combination with their patented vaccine ... ITI and Duke University, are based on the work ... Division of Neurosurgery at The Preston Robert Tisch Brain ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... The National Model Aviation Museum, located at ... to announce that it has been granted full civilian ... States Air Force. , The certification is the culmination ... spring with an on-site inspection by Sarah Sessions, Museum ... National Museum of the United States Air Force ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... revenue growth ... - Product revenues increased 30% to a record $59.7 ... - Shipped 28,600 new pulse oximeters ... increased 104%, IRVINE, Calif., April 29, 2008 Masimo,Corporation (Nasdaq: MASI ), the ...
... to transmit medical images via cellular phones that has ... Jerusalem researcher has the potential to provide sophisticated radiological ... population lacking access to such technology. This would include ... rural areas of developed countries who live considerable distances ...
... /PRNewswire-FirstCall/,-- Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY), ... publication of the,Prospectus by Shire Limited on 16 ... to 700,000,000 Ordinary Shares of 5 pence each ... be made available through,publication on Shire,s website: ...
Cached Biology Technology:Masimo Reports First Quarter 2008 Financial Results 2Masimo Reports First Quarter 2008 Financial Results 3Masimo Reports First Quarter 2008 Financial Results 4Masimo Reports First Quarter 2008 Financial Results 5Masimo Reports First Quarter 2008 Financial Results 6Masimo Reports First Quarter 2008 Financial Results 7Masimo Reports First Quarter 2008 Financial Results 8Masimo Reports First Quarter 2008 Financial Results 9Masimo Reports First Quarter 2008 Financial Results 10Researchers develop method for transmitting medical images via cell phones 2Researchers develop method for transmitting medical images via cell phones 3Researchers develop method for transmitting medical images via cell phones 4Publication of Supplementary Prospectus 2Publication of Supplementary Prospectus 3Publication of Supplementary Prospectus 4
(Date:7/28/2014)... Brain & Behavior Research Foundation today announced the ... recognizing exceptional clinical and basic research by young ... Investigator Grants. The grants enable early career scientists ... research for the prevention, early detection, treatment, and ... four people. , Six young scientistswinners of the ...
(Date:7/28/2014)... 15% of adults suffer from fertility problems, many of ... a paradox: We might expect such genes, which reduce ... population. Research at the Weizmann Institute of Science that ... have solved this riddle. Not only can it explain ... open new avenues in understanding the causes of genetic ...
(Date:7/27/2014)... has revealed that nicotine and cotinine, a metabolite of ... certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or ... and ultimately ends up in the tobacco smoke. Once ... where it is activated by a variety of enzymes ... revealed that nicotine can partially interfere with the activation ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Mutations from Venus, mutations from Mars 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... forces apparatus and an atomic force microscope, researchers at UC ... interactions, leading to insights into demyelinating diseases, such as multiple ... the National Academy of the Sciences . For a ... nerve cells that run throughout our bodies must be ...
... GA--Managing the quality and quantity of freshwater resources ... of the 21st century. Global population growth and ... water resources among domestic, industrial, and agricultural users. ... while recognizing the limitations of freshwater resources, many ...
... on climate protection and political declarations of intent, ... the contrary, they continue to increase. With a ... markets such as India and China the emission ... to be unlikely. Therefore, large-scale methods to artificially ...
Cached Biology News:Unhealthy attachments 2Unhealthy attachments 3Report details multiple commercial uses of wireless sensor networks 2Climate engineering: Minor potential, major side effects 2Climate engineering: Minor potential, major side effects 3
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: